FLT3-IN-13 

FLT3-IN-13 (compound 20) is a potent and effective antileukemic topoisomerase II and FLT3 dual inhibitor with IC₅₀ values of 2.26 μM and 2.26 μM, respectively. FLT3-IN-13 arrests cell cycle at G2/M phase and induce apoptosis. FLT3-IN-13 has anticytotoxic activity, particularly against leukemia^[1].

IC₅₀: 2.26 μM (TOPO II), 2.26 μM (FLT3)^[1]

FLT3-IN-13 (compound 20) has strong antiproliferative activity against HL-60 with an IC₅₀ of 0.48 ± 0.08 μM^[1].
FLT3-IN-13 arrests HL-60 cell cycle at G2/M phase (G1%: 24.76±1.00, S%: 21.26±1.72, G2%: 32.78±2.21, total apoptosis%: 21.36±2.73)^[1].
FLT3-IN-13 induces apoptosis of HL-60 with early-apoptosis of 6.13±1.20% and late-apoptosis of 13.06±0.40%^[1].
FLT3-IN-13 significantly upregulates P53, TNFα and caspase 3/7 proteins in the HL-60 cell line, and increases the Bax/Bcl-2 ratio^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

342.35

C₂₀H₁₄N₄O₂

O=C1C2=C(C(C(N/N=C/C3=CC=NC=C3)=O)=CC=C2)NC4=C1C=CC=C4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Abdelgawad MA, et al. Design, synthesis, and biological evaluation of novel pyrido-dipyrimidines as dual topoisomerase II/FLT3 inhibitors in leukemia cells. Bioorg Chem. 2022 May;122:105752.  [Content Brief]